VIA
ALNY icon

Vantage Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vantage Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$57K Hold
655
– – 0.01% 263
2018
Q2 		$65K Hold
655
– – 0.02% 238
2018
Q1 		$78K Buy
655
+400
+157% +$51.6K 0.02% 231
2017
Q4 		$32K Buy
255
+100
+65% +$12.6K 0.01% 369
2017
Q3 		$18K Buy
155
+128
+474% +$10.9K ﹤0.01% 453
2017
Q2 		$2K Hold
27
– – ﹤0.01% 700
2017
Q1 		$1K Hold
27
– – ﹤0.01% 727
2016
Q4 		$1K Hold
27
– – ﹤0.01% 742
2016
Q3 		$2K Hold
27
– – ﹤0.01% 677
2016
Q2 		$1K Hold
27
– – ﹤0.01% 757
2016
Q1 		$2K Hold
27
– – ﹤0.01% 703
2015
Q4 		$3K Hold
27
– – ﹤0.01% 659
2015
Q3 		$2K Buy
+27
New +$3K ﹤0.01% 697

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.6B AUM 48.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return